Tonix Pharma expects results on fibromyalgia test during H2, shares +5.7%

|About: Tonix Pharmaceuticals Holdi... (TNXP)|By:, SA News Editor

Tonix Pharmaceuticals (TNXP +5.7%) says it expects to report results from Phase IIb testing of its TNX-102 SL drug candidate in patients with fibromyalgia during H2 2014.

TNXP says it began enrollment in the BESTFIT trial last September which was expected to monitor ~120 patients split equally between groups receiving either TNX-102 SL or placebo, measuring changes in pain intensity.

TNXP also says it expects to begin a trial of TNX-102 SL as a potential treatment for post-traumatic stress disorder and tension-type headache during Q3 and Q4, respectively.